Statin Regulation of CYP3A4 and CYP3A5 Expression
- 17 June 2009
- journal article
- review article
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 10 (6) , 1017-1024
Abstract
CYP3A4 and CYP3A5 are cytochrome P450 enzymes that are highly expressed in the liver and gut and metabolize endogenous compounds and xenobiotics. Statins are cholesterol-lowering drugs that are extensively metabolized by CYP3A4 and CYP3A5. The bioavailability of statins is affected by CYP3A4 and CYP3A5 and glucuronidases metabolism as well as uptake and efflux transporters that affect drug disposition. CYP3A4 and CYP3A5 variants have been demonstrated to influence the pharmacokinetics, efficacy and safety of statins. Inducers and inhibitors of CYP3A4 and CYP3A5 play an important role in reducing statin efficacy and increase the risk of adverse effects, respectively. Statins have been demonstrated to increase CYP3A expression in vitro, most likely because they are ligands to nuclear receptors (pregnane X receptor and constitutive androsterone receptor) that form heterodimers with retinoid X receptors and bind to responsive elements in the CYP3A4 and CYP3A5 promoter regions. This special report outlines the earlier studies on variability of response to statins owing to CYP3A variants and highlights findings on the induction of CYP3A4 and CYP3A5 expression by statins.Keywords
Funding Information
- São Paulo Research Foundation
This publication has 48 references indexed in Scilit:
- Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformationAnalytical and Bioanalytical Chemistry, 2008
- Retinoids induce cytochrome P450 3A4 through RXR/VDR-mediated pathwayBiochemical Pharmacology, 2008
- Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative SubstratesDrug Metabolism Reviews, 2008
- Impact of Population Admixture on the Distribution of the CYP3A5*3 PolymorphismPharmacogenomics, 2007
- Cytochrome P4503APolymorphisms and Immunosuppressive Drugs: An UpdatePharmacogenomics, 2007
- Cytochrome P450 3A5 Genotype is Associated with Verapamil Response in Healthy SubjectsClinical Pharmacology & Therapeutics, 2007
- CYP3A5 Genotype has an Impact on the Metabolism of the HIV Protease Inhibitor SaquinavirClinical Pharmacology & Therapeutics, 2007
- The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatmentClinical Pharmacology & Therapeutics, 2005
- Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the and genesClinical Pharmacology & Therapeutics, 2004
- Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expressionNature Genetics, 2001